Fifty-Year-Old Urine Drug Tests Are Misleading Doctors and Harming Patients, Experts Warn

When a physician orders a diagnostic test, an implicit promise is made: the result will be interpreted carefully, with the patient’s interests at the center. Medical education devotes enormous energy to teaching trainees when to test, how to contextualize results, and when to avoid testing altogether. Most internal medicine residents can fluently explain the strengths and pitfalls of a D-dimer for suspected pulmonary embolism or NT-proBNP for possible heart failure. Yet according to a viewpoint published in the Journal of General Internal Medicine, one test is ordered and acted upon with strikingly little nuance despite its power to reshape patient care: the urine drug test, or UDT.

Dustin Kee of Johns Hopkins University School of Medicine, John Buyske and Ashish Thakrar of the University of Pennsylvania Perelman School of Medicine argue that the urine drug test has been absorbed into routine clinical practice without the interpretive guardrails applied to virtually every other diagnostic tool. Used both as a targeted diagnostic and, at the population level, as a screen, the technology behind most UDTs is an immunoassay, a method that detects antibody binding to an entire drug class and rapidly returns a presumptive positive or negative result. That speed and binary simplicity, the authors write, confer a false sense of precision that masks serious limitations: immunoassays cross-react with commonly prescribed medications, miss many of the synthetic compounds that now dominate the unregulated drug supply, and can remain positive well beyond any clinically relevant window of intoxication.

The analytical logic explains why. An immunoassay does not identify a specific molecule; it recognizes structural features shared across a class of compounds. Anything in the urine that mimics those features can trigger a positive signal, whether or not the patient took the drug in question. Conversely, if the target compound lacks the structural features the antibody was designed to detect, the test returns a negative even when the drug is present. Results therefore must be interpreted against the clinical history, the physical examination for signs of intoxication or withdrawal, and basic pharmacology, with confirmatory mass spectrometry when precision matters. In practice, the authors observe, the UDT alone frequently drives management decisions.

The historical trajectory helps explain how medicine arrived here. The immunoassay-based UDT rose to prominence in the early 1970s, first through Operation Golden Flow, the mass screening program for returning Vietnam War veterans, and then through Nixon-era federal methadone regulations that mandated routine urine testing. At the time, the drug supply consisted largely of a few plant-derived substances such as heroin, opium, and cocaine, a narrow and stable set of targets to which immunoassays were reasonably well suited, in an era when fewer medications existed to cross-react and confound results. Workplace screening later became embedded in occupational health and Department of Transportation protocols, and only afterward migrated into routine clinical medicine, adopted without adequate refinement or clinician training and applied to diagnostic questions it was never designed to answer.

The chemistry of modern confounding is remarkable. Bupropion, an antidepressant, and labetalol, a blood pressure medication, both cross-react with amphetamine immunoassays. Dextromethorphan, the ubiquitous cough suppressant, can produce a false positive for phencyclidine, and the antidepressant sertraline can mimic benzodiazepines. False negatives are just as systematic. Fentanyl, now the dominant opioid in the unregulated supply, along with methadone and buprenorphine, the cornerstone treatments for opioid use disorder, are synthetic or semi-synthetic compounds that the standard opiate immunoassay does not detect at all, because that assay specifically targets plant-based opiates derived from the poppy. Benzodiazepine immunoassays, optimized for diazepam, perform poorly for clonazepam and many other drugs in the class, as well as for designer benzodiazepines such as bromazolam increasingly encountered in the illicit market. Detection windows also stretch far beyond intuition: with chronic use, fentanyl can be detected more than 21 days after the last exposure. And because immunoassays are strictly qualitative, they confirm exposure but cannot quantify concentration, ruling out any assessment of impairment or clinical severity.

Against this backdrop, the evidence on physician interpretation is sobering. In a study by Starrels and colleagues, internal medicine residents scored a mean of just 3.0 out of 7 on an assessment of urine drug test interpretation, yet 56 percent reported confidence in their evaluations. Confidence did not track with accuracy: 73 percent of the confident residents scored 3 or lower. Chua and colleagues documented similar deficits at the bedside, finding that clinicians documented an interpretation for only 55 percent of UDT results in outpatient clinics, and that expert toxicologist review identified misinterpretation in 28 percent of those documented cases.

These are not abstract statistics. The authors recount cases from their own practices in which a single misread test caused direct harm. One woman, admitted for an acute illness, had reported faithful adherence to prescribed clonazepam, but when her urine test came back negative, the inpatient team abruptly stopped the medication, precipitating benzodiazepine withdrawal and a panic attack. Another patient arrived in the intensive care unit with respiratory failure from a synthetic opioid overdose, yet a negative opiate immunoassay sent the team searching for other causes and delayed definitive treatment. A third patient presenting with chest pain tested falsely positive for amphetamines because of prescribed trazodone, and his pain was initially misattributed to stimulant use, hindering timely diagnosis. In each case, premature diagnostic closure built on one misinterpreted test led to preventable injury.

The authors’ first remedy is educational. They call for a formal urine drug testing and medical toxicology curriculum woven into internal medicine residency training, covering consent before ordering, the distinction between immunoassays and the more sensitive and specific technique of mass spectrometry, individual drug metabolism and detection windows, and the common false positives and false negatives that arise from an increasingly synthetic drug supply. Clinicians should know which targeted and confirmatory assays exist beyond the standard panel and when to deploy them, and they must learn to recognize substance-specific toxidromes so that clinical presentation, not a presumptive lab value, drives initial management. Greater diagnostic fluency, they argue, would reduce over-reliance on the UDT and prompt earlier consultation with toxicology or addiction medicine specialists while confirmatory results are pending. Some curricular components have been described before, but they have never been integrated into standardized training in internal medicine or the other specialties that order these tests most often.

Education alone, however, cannot compensate for assays frozen in time. The regulatory lag is stark: although fentanyl became the leading driver of opioid overdose mortality by the early 2010s, a CLIA-waived point-of-care fentanyl immunoassay usable at the bedside without specialized laboratory infrastructure did not become available until 2023, a full decade later, and availability remains limited in many health systems. Standard benzodiazepine panels still fail to detect the metabolites of the most commonly encountered compounds. No FDA-cleared test exists for xylazine, the adulterant associated with severe wounds, nor for medetomidine, which can trigger a severe withdrawal syndrome of abrupt onset. The authors urge expanded access to timely, in-house mass spectrometry, which can query a far wider range of substances and adulterants, deliver quantitative drug levels, and resolve both false positives and false negatives on screening immunoassays. Today’s send-out confirmatory processes, they note, can take days, an eternity when treatment decisions hang in the balance.

The viewpoint closes with a warning that misreading a urine drug test is never a benign error. It shapes diagnoses, steers clinical decisions, and compounds the stigma already borne by patients with substance use disorders, a population for whom a suspicious result can mean the difference between compassionate care and dismissal. While efforts to curb unnecessary testing have gained ground in addiction medicine, urine drug testing remains deeply embedded in general medicine largely without the interpretive scaffolding applied to other tests. The implicit promise attached to every test order, the authors conclude, deserves more than current practice delivers, and closing that gap through formalized residency education and modernized assays is, they write, long overdue.

Subject of Research: Interpretation and limitations of urine drug testing in clinical medicine

Article Title: Closing the Interpretive Gap in Urine Drug Testing: A Call for Education and Assay Modernization

Article References: Kee, D. P., Buyske, J. J., & Thakrar, A. P. (2026). Closing the Interpretive Gap in Urine Drug Testing: A Call for Education and Assay Modernization. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10919-0

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10919-0

Keywords: urine drug testing, immunoassay, false positives, false negatives, fentanyl, toxicology, medical education, mass spectrometry, substance use disorder, benzodiazepines, opioid use disorder, drug screening